Emergent Biosolutions (EBS) revenue breakdown
By segment, MCM Products is the largest at 67% of fiscal 2025 revenue, growing 1% a year over 2 years.
By product, MCM Product sales is the largest at 61% of fiscal 2025 revenue, growing 1% a year over 2 years.
Revenue by segment
Fiscal years, as Emergent Biosolutions reports them in its 10-K filings; fiscal 2025 total $683M.
| Segments | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| MCM Products | $447M | $510M | $457M | 67% |
| Commercial Products | $497M | $399M | $226M | 33% |
Revenue by product
Fiscal years, as Emergent Biosolutions reports them in its 10-K filings; fiscal 2025 total $743M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| MCM Product sales | — | — | — | — | — | — | $447M | $510M | $457M | 61% |
| Commercial Product sales | — | — | — | — | — | $438M | $497M | $399M | $226M | 30% |
| All other revenues | — | — | — | — | — | — | $105M | $135M | $60M | 8% |
| Total Product sales, net | $296M | $422M | $606M | $904M | $990M | $1.0B | — | — | — | — |
| Services | $49M | $69M | $99M | $80M | $450M | $310M | — | — | — | — |
| Contracts and grants | $143M | $70M | $77M | $122M | $115M | — | — | — | — | — |
Revenue by region
Fiscal years, as Emergent Biosolutions reports them in its 10-K filings; fiscal 2025 total $743M.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $421M | $440M | $598M | $675M | $1.4B | $1.6B | $886M | $607M | $823M | $531M | 71% |
| Other | — | — | — | — | $63M | $84M | $83M | $218M | $81M | $137M | 18% |
| Canada | — | — | — | — | $46M | $67M | $149M | $224M | $140M | $75M | 10% |
| Non-U.S. Government | $68M | $121M | $185M | $431M | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for EBS.
Open EBS in InvestinglyQuestions
Where does Emergent Biosolutions make its money?
In fiscal 2025, by segment: MCM Products $457M, Commercial Products $226M.
From Emergent Biosolutions's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.